Abstract 1873P
Background
Patients living with myeloproliferative neoplasms (MPN), including myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythemia (ET), should engage in self-care behaviours to improve their health. This study aims to preliminary assess self-care behaviours in MPN patients.
Methods
A descriptive cross-sectional study has been conducted in 9 haematology centres in Italy since November 2021. The Italian Association of MPN Patients (AIPAMM) promoted this study. The Self-Care in MyeloProliferative Neoplasms Inventory (SC-MPNI), a 31-item questionnaire measuring self-care behaviours according to the Middle-Range Theory of Self-Care of Chronic Illness, was developed and tested for its content validity. MPN patients were asked to complete a paper-and-pencil questionnaire during their outpatient visit or at home.
Results
Preliminary data from 171 patients (54% male; mean age=58, SD=19) and 5 centres were analysed (45.6% of the expected sample). Participants were living with overt MF (n=51), prefibrotic MF (n=24), PV (n=48) or ET (n=44). Concerning self-care maintenance, the most frequent behaviour was attending all scheduled clinical appointments (M=5.9, SD=0.6), and the least used one was performing activities that improve mental and physical well-being (M=3.1, SD=1.7). Concerning self-care monitoring, the most frequent behaviour was getting blood tests as prescribed by the haematologist (M=5.9, SD=0.5), and the least used one was checking any measurement the healthcare providers recommend (M=4.7, SD=1.4). Concerning self-care management, the most frequent behaviour was accurately reporting symptoms to the healthcare providers during visits to get a comprehensive response (M=5.5, SD=0.9), and the least used one was asking for psychological support to overcome emotional problems (M=2.6, SD=1.5).
Conclusions
This study will contribute to assessing self-care behaviours in patients with MPN. Health professionals should support innovative interventions to promote self-care, which is crucial for MPN patients to reduce cardiovascular events and be medically fit to undergo hematopoietic stem cell transplantation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05